#USA #New York #Faruqi & Faruqi #investment loss #Rezolute

Investigation of Rezolute, Inc.

Faruqi & Faruqi, LLP, a leading national securities law firm known for its advocacy on behalf of investors, has announced an investigation into potential claims against Rezolute, Inc. (NASDAQ: RZLT). This inquiry follows a drastic fall in the company's stock price, which has affected numerous investors.

On December 11, 2025, shares of Rezolute experienced a shocking decline from approximately $10.94 to an intraday low of around $0.90—an alarming drop of about 85% to 90%. This drastic fall came in response to the company's disappointing results from its Phase 3 clinical trial for ersodetug, its lead drug candidate aimed at treating congenital hyperinsulinism. In the trial, Rezolute failed to achieve both its primary and crucial secondary endpoints, indicating that the highest dose showed reductions in hypoglycemia events, but these were not statistically significant compared to the placebo group.

Such a critical failure in clinical trials can severely impact investor confidence, prompting firms like Faruqi & Faruqi to step in. This law firm, founded in 1995, has a significant track record—having recovered hundreds of millions for investors in various cases over the years.

James (Josh) Wilson, a senior partner at Faruqi & Faruqi, expressed the firm's commitment to supporting investors who have sustained substantial losses in Rezolute. He urges affected investors to reach out to discuss their legal rights and explore potential courses of action. Interested parties can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi is not only committed to helping with current cases but also aims to keep its community informed about developments concerning Rezolute. They encourage investors and interested individuals to check their website, which provides further resources and details concerning this investigation.

Conclusion

The investigation by Faruqi & Faruqi is a pressing reminder of the volatility inherent in the pharmaceutical sector, particularly regarding clinical trial outcomes. As the law firm progresses with its inquiries, it highlights the need for thorough due diligence when investing in biotech stocks. Investors are urged to keep abreast of updates and consider seeking professional counsel if they feel they have been negatively impacted by Rezolute's recent developments.

For more information about the Rezolute investigation, visit Faruqi & Faruqi's website or follow them on their social platforms for timely updates.